tetano
Editor, Senior Moderator
Paediatr Respir Rev. 2014 Jun 28. pii: S1526-0542(14)00077-3. doi: 10.1016/j.prrv.2014.06.002. [Epub ahead of print]
Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: the Quebec Experience.
Quach C.
Author information
Abstract
Given the burden of illness associated with influenza, vaccination is recommended for individuals at high risk of complications. The live-attenuated influenza vaccine (LAIV) is administered by intranasal spray, thus directly stimulating mucosal immunity. In this review, we aimed to provide evidence for its efficacy and safety in different paediatric populations. We also share the Quebec experience of LAIV use through a publicly funded vaccination program for children with chronic, high-risk conditions.
RESULTS:
from randomized controlled trials in healthy children and in asthmatics have demonstrated superior efficacy of LAIV over the injectable vaccine (IIV). LAIV is well tolerated: its administration is associated with runny nose and nasal congestion, but not with asthma exacerbations and is well tolerated in children with cystic fibrosis, when compared to IIV. The vaccine is well accepted by children and parents and can easily be part of vaccination clinics in paediatric tertiary care centres targeting children with chronic, high-risk conditions, not leading to immunosuppression.
Copyright ? 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Asthma; Children; Cystic fibrosis; Live-attenuated influenza vaccine
PMID:
25242731
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25242731
Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: the Quebec Experience.
Quach C.
Author information
Abstract
Given the burden of illness associated with influenza, vaccination is recommended for individuals at high risk of complications. The live-attenuated influenza vaccine (LAIV) is administered by intranasal spray, thus directly stimulating mucosal immunity. In this review, we aimed to provide evidence for its efficacy and safety in different paediatric populations. We also share the Quebec experience of LAIV use through a publicly funded vaccination program for children with chronic, high-risk conditions.
RESULTS:
from randomized controlled trials in healthy children and in asthmatics have demonstrated superior efficacy of LAIV over the injectable vaccine (IIV). LAIV is well tolerated: its administration is associated with runny nose and nasal congestion, but not with asthma exacerbations and is well tolerated in children with cystic fibrosis, when compared to IIV. The vaccine is well accepted by children and parents and can easily be part of vaccination clinics in paediatric tertiary care centres targeting children with chronic, high-risk conditions, not leading to immunosuppression.
Copyright ? 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Asthma; Children; Cystic fibrosis; Live-attenuated influenza vaccine
PMID:
25242731
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25242731